[
    [
        {
            "time": "",
            "original_text": "富时罗素季度调整结果出炉，长城汽车、中远海控纳入富时中国A50指数",
            "features": {
                "keywords": [
                    "富时罗素",
                    "季度调整",
                    "长城汽车",
                    "中远海控",
                    "富时中国A50指数"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "汽车",
                    "航运"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "富时罗素季度调整结果出炉，长城汽车、中远海控纳入富时中国A50指数",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国元证券下调华兰生物评级至增持，华兰生物2021年中报点评：业绩短期承压，流感疫苗有望放量 投资评级恶化",
            "features": {
                "keywords": [
                    "国元证券",
                    "华兰生物",
                    "评级下调",
                    "业绩承压",
                    "流感疫苗"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "国元证券下调华兰生物评级至增持，华兰生物2021年中报点评：业绩短期承压，流感疫苗有望放量 投资评级恶化",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "每日报告回放",
            "features": {
                "keywords": [],
                "sentiment_score": 0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "每日报告回放",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 1,
                "Impact": 1,
                "Duration": 1,
                "Entity_Density": 1,
                "Market_Scope": 1,
                "Time_Proximity": 5,
                "Headline_Structure": 3,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "华兰生物：上半年总营收与净利润均同比下降，疫苗制品营收同比增加206.67% 盈利能力下降",
            "features": {
                "keywords": [
                    "华兰生物",
                    "总营收",
                    "净利润",
                    "疫苗制品",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华兰生物：上半年总营收与净利润均同比下降，疫苗制品营收同比增加206.67% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
            "features": {
                "keywords": [
                    "医药",
                    "健康护理",
                    "智飞生物",
                    "新冠疫苗",
                    "III期数据",
                    "变异株"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "20股获高管增持 华兰生物获增持金额最多",
            "features": {
                "keywords": [
                    "高管增持",
                    "华兰生物"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "20股获高管增持 华兰生物获增持金额最多",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "西部证券维持华兰生物买入评级，2021年半年报点评：血制品短期承压，长期看好疫苗板块",
            "features": {
                "keywords": [
                    "西部证券",
                    "华兰生物",
                    "买入评级",
                    "血制品",
                    "疫苗板块"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "西部证券维持华兰生物买入评级，2021年半年报点评：血制品短期承压，长期看好疫苗板块",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "私募大佬持仓出炉！冯柳、邓晓峰、葛卫东、裘国根、赵军等心水股有哪些",
            "features": {
                "keywords": [
                    "私募大佬",
                    "冯柳",
                    "邓晓峰",
                    "葛卫东",
                    "裘国根",
                    "赵军",
                    "持仓"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "私募大佬持仓出炉！冯柳、邓晓峰、葛卫东、裘国根、赵军等心水股有哪些",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]